Ultragenyx Pharmaceutical Inc. (RARE) Stock Price & Analysis
Ultragenyx Pharmaceutical Inc. (RARE) closed at USD 16.78 on Thursday, October 29, 2026, down 2.44% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 17.2; the Oct 29, 2026 session ranged USD 16.71–17.63 on volume of 2,801,674 shares. Market capitalization is $1.65B, with a 52-week range of USD 12.73–39.89 (NMS). Source: Nexqual, retrieved October 29, 2026 at 20:55 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RARE.md
Key facts (RARE)
- Last four reported quarters (through Jun 30, 2026): revenue $717M, net income -$586M (-81.7% margin), free cash flow -$489M (SEC filings).
- Insider open-market sales, last ~7 months: 12 Form 4 filings, $924K; 4 not under a Rule 10b5-1 plan ($169K); 0 by opportunistic insiders, 5 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.43 on a 1–5 scale) (21 analysts), mean target USD 26.25 (range 16–39).
- Total return with dividends: 1Y -52.3% vs S&P 500 +14.4%; 5Y -80.0% vs S&P 500 +79.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.75, revenue estimate $184M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RARE)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $351M | $363M | $434M | $560M | $673M | $717M |
| Operating income | -$382M | -$649M | -$569M | -$536M | -$535M | -$528M |
| Net income | -$454M | -$707M | -$607M | -$569M | -$575M | -$586M |
| EPS (diluted) | -$6.70 | -$10.12 | -$8.25 | -$6.29 | -$5.83 | — |
| Free cash flow | -$412M | -$497M | -$519M | -$421M | -$472M | -$489M |
| Operating margin | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% | -73.6% |
| Net margin | -129.2% | -194.7% | -139.9% | -101.6% | -85.4% | -81.7% |
| Revenue growth | +29.7% | +3.4% | +19.5% | +29.0% | +20.2% | — |
| Cash + short-term investments | $740M | $748M | $578M | $610M | $680M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (RARE)
P/S 2.3x · FCF yield -29.56% · Earnings yield -35.42%
Insider sales (SEC Form 4, open-market, last ~7 months) (RARE)
8 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Horn Howard | Chief Financial Officer | 7,066 | $108K | 7.3% | No | Too little history (no open-market trades in 2023) |
| 2026-09-15 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 1,283 | $17K | 1.9% | Yes | Routine (sold in Mar & Sep each year 2023–2025) |
| 2026-09-03 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 161 | $2K | 0.2% | No | Routine (sold in Mar & Sep each year 2023–2025) |
| 2026-08-03 | Parschauer Karah Herdman | EVP and Chief Legal Officer | 1,900 | $47K | 2% | Yes | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-08-03 | Horn Howard | Chief Financial Officer | 4,696 | $117K | 4.6% | Yes | Too little history (no open-market trades in 2023) |
| 2026-07-01 | Horn Howard | Chief Financial Officer | 4,698 | $156K | 4.4% | Yes | Too little history (no open-market trades in 2023) |
| 2026-06-15 | Sanders Corazon (corsee) D. | Director | 2,000 | $50K | 8.7% | No | Routine (sold in Jun each year 2023–2025) |
| 2026-06-15 | Parschauer Karah Herdman | EVP and Chief Legal Officer | 1,899 | $47K | 2% | Yes | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-06-01 | Horn Howard | Chief Financial Officer | 4,653 | $111K | 4.2% | Yes | Too little history (no open-market trades in 2023) |
| 2026-05-18 | Suliman Shehnaaz | Director | 5,740 | $144K | 17% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-05 | Crombez Eric | EVP and Chief Medical Officer | 344 | $9K | 0.3% | No | Too little history (no open-market trades in 2023) |
| 2026-05-01 | Horn Howard | Chief Financial Officer | 4,683 | $117K | 4.1% | Yes | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (RARE)
Consensus Buy (mean 2.43 on a 1–5 scale), 21 analysts; mean target USD 26.25 (low 16, high 39).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | UBS | Initiated | Neutral | $16 |
| 2026-09-21 | Evercore ISI Group | Target raised | In-Line | $16 → $18 |
| 2026-09-21 | Barclays | Target raised | Overweight | $32 → $35 |
| 2026-09-18 | Morgan Stanley | Target raised | Equal-Weight | $18 → $20 |
| 2026-09-18 | Citigroup | Target raised | Buy | $31 → $32 |
| 2026-09-18 | Canaccord Genuity | Target raised | Buy | $37 → $39 |
| 2026-09-18 | Cantor Fitzgerald | Target raised | Overweight | $33 → $39 |
| 2026-09-17 | Citigroup | Target raised | Buy | $28 → $31 |
| 2026-09-04 | Goldman Sachs | Target lowered | Neutral | $28 → $19 |
| 2026-09-04 | Barclays | Target lowered | Overweight | $43 → $32 |
| 2026-09-03 | JP Morgan | Downgrade | Overweight → Neutral | $80 → $36 |
| 2026-09-03 | Jefferies | Target lowered | Buy | $77 → $28 |
Total return (dividends reinvested) (RARE)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -52.3% | -80.0% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | -52.4% | -27.5% |
| Volatility (annualized) | 96.6% | 56.2% |
| Max drawdown | -64.8% (Dec 2025→Sep 2026) | -83.3% (Apr 2022→Sep 2026) |
RARE earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 4, 2026 | Quarter ended Jun 30, 2026 | −$0.90 | −$1.00 | Beat +10.0% | -0.4% |
| May 5, 2026 | Quarter ended Mar 31, 2026 | −$1.54 | −$1.46 | Miss −5.5% | +4.5% |
| Feb 12, 2026 | Quarter ended Dec 31, 2025 | −$1.29 | −$1.17 | Miss −10.3% | -14.1% |
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | −$1.29 | −$1.17 | Miss −10.3% | +7.1% |
| Nov 4, 2025 | Quarter ended Sep 30, 2025 | −$1.81 | −$1.21 | Miss −49.6% | -4.8% |
| Aug 5, 2025 | — | — | — | — | -1.4% |
| May 6, 2025 | — | — | — | — | -14.0% |
| Feb 13, 2025 | — | — | — | — | -2.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
RARE recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 20, 2026 | Schedule 13G | Madison Avenue International LP, Madison Avenue Partners, LP: 6.4% of shares, passive 5%+ holder |
| Oct 19, 2026 | 8-K | Other material event “On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") and Baylor Research Institute ("BRI") entered into a settlement agreement with Navinta LLC ("Navinta") resolving patent litigation related to patents covering the Company's DOJOLVI (triheptanoin) oral liquid. The litigation, which was filed in the United States District Court for the District of New Jersey, resulted from the submission by Navinta of an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration seeking…” |
| Oct 14, 2026 | 8-K | Entered a material agreement “On October 8, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") entered into an asset purchase agreement (the "PRV Asset Purchase Agreement"), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher ("PRV") to the buyer. The Company was awarded the PRV by the U.S. Food and Drug Administration ("FDA") on September 17, 2026 upon approval of FAYUVI TM (rebisufligene etisparvovec-hopf) also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis type…” |
| Oct 7, 2026 | 8-K | Entered a material agreement “On October 6, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") entered into an asset purchase agreement (the "PRV Asset Purchase Agreement"), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher ("PRV") to the buyer. The Company was awarded the PRV by the U.S. Food and Drug Administration ("FDA") on August 19, 2026 upon approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen…” |
| Sep 17, 2026 | 8-K | Other material event “On September 17, 2026, Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") announced that the U.S. Food and Drug Administration (the "FDA") granted standard full approval of FAYUVI (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A). FAYUVI is the first-ever FDA-approved treatment for Sanfilippo syndrome Type A, a progressive and fatal neurodegenerative disease, and the second gene…” |
| Sep 2, 2026 | 8-K | Other material event “On September 2, 2026, Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") announced results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome. The study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index ("MDRI"). The safety profile observed in Aspire was consistent with Phase 1/2. In Aspire , the randomized groups were comparable at baseline and consistent…” |
| Aug 19, 2026 | 8-K | Other material event “On August 19, 2026, Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") announced the U.S. Food and Drug Administration (the "FDA") granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). Clinical Program and Post-Marketing Study Requirements Supporting Accelerated Approval of GENGLYCOS The approval of GENGLYCOS is based on positive data from the 48-week…” |
| Aug 14, 2026 | Schedule 13G | RTW Investments, LP, Roderick Wong: 7.9% of shares, passive 5%+ holder |
| Aug 13, 2026 | Schedule 13G | passive 5%+ holder |
| Aug 11, 2026 | 8-K | Other material event |
| Aug 7, 2026 | Schedule 13G | passive 5%+ holder |
| Aug 5, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 4, 2026 | 8-K | Quarterly results |
| Jul 31, 2026 | Schedule 13G/A | passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
RARE revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $112.0M | 52.3% | +38.3% |
| Royalty | $102.0M | 47.7% | +18.6% |
| Total revenue | $214.0M | 100% | — |
RARE revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| North America | $121.0M | 56.5% | +17.5% |
| Latin America | $51.0M | 23.8% | +54.5% |
| EMEA | $35.0M | 16.4% | +29.6% |
| Asia Pacific | $7.0M | 3.3% | +75.0% |
| Total revenue | $214.0M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
RARE suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Kyowa Kirin | “Please see "—License and Collaboration Agreements—Approved Products— Kyowa Kirin Co., Ltd." for a description of our collaboration and license agreement with KKC.” |
| Partner | REGENXBIO Inc. (RGNX) | “Please see "—License and Collaboration Agreements—Clinical Product Candidates—REGENXBIO Inc." for a description of our license agreement with REGENXBIO Inc.” |
| Partner | GeneTx Biotherapeutics | “Please see "—License and Collaboration Agreements—Clinical Product Candidates—GeneTx" for a description of our license agreement with GeneTx Biotherapeutics LLC, or GeneTx.” |
| Partner | Daiichi Sankyo | “We have in the past sought and may in the future seek funds through a sale of future royalty payments similar to our transactions with Royalty Pharma and OMERS or through collaborative partnerships, strategic alliances, and licensing or other arrangements, such as our transaction with Daiichi Sankyo Co., Ltd. and we may be required to relinquish rights to some of our technologies or product candidates, future reve…” |
| Partner | Cowen and Company | “In February 2024, we entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, pursuant to which the Company may offer and sell shares of the Company's common stock having an aggregate offering proceeds up to $350 million, from time to time, in ATM offerings through Cowen.” |
Quoted from the company's 10-K filed Feb 18, 2026.
Companies that name RARE in their SEC reports
| Relationship to RARE | Company | Filing | Sentence |
|---|---|---|---|
| partner | Solid Biosciences Inc. (SLDB) | 10-K Mar 19, 2026 | “In October 2020, the license agreement was amended such that we were required to pay the University of Washington $375 thousand in connection with the execution of the collaboration and license agreement ("the Collaboration Agreement") with Ultragenyx Pharmaceutical Inc. ("Ultragenyx") in October 2020.” |
| partner | ABEONA THERAPEUTICS INC. (ABEO) | 10-K Mar 17, 2026 | “Under the terms of our agreement with Ultragenyx, we are eligible to receive payments based on the achievement of certain sales” |
| partner | REGENXBIO Inc. (RGNX) | 10-K Mar 5, 2026 | “Prior to the maturity date, interest and principal under the 2025 Royalty Bond shall be paid quarterly to HCR solely using proceeds received from certain specified royalties, milestone payments, license fees and other consideration payable to the Company under specified license agreements (collectively, the Royalty Interest), including (i) the Novartis License for Zolgensma and Itvisma, (ii) the collaboration and …” |
RARE company outlook (results filed Aug 4, 2026)
- “Guidance • Total revenue in the second quarter of 2026 was $214 million.”
- “The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from potential new product launches. • Crysvita revenue in the second quarter of 2026 was $156 million, consistent with expected seasonality in the U.S. and Canada and ordering patterns in Latin America.”
- “The company reaffirms its full year 2026 Crysvita revenue guidance of $500 million to $520 million . • Dojolvi revenue in the second quarter 2026 was $27 million.”
- “The company reaffirms its full year 2026 Dojolvi revenue guidance of $100 million to $110 million. • Evkeeza® revenue in the second quarter 2026 was $21 million, driven by increased demand from new country launches and early access. • Mepsevii® revenue in the second quarter 2026 was $10 million.”
Analysts expect $183.7M for the current quarter, 75.3% below the midpoint of the company's guidance ($745.0M).
Quoted word-for-word from the SEC 8-K results press release.
RARE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.75 | $-0.73 | −$0.02 | $183.7M | 6 |
| Next quarter (ends Dec 2026) | $-0.66 | $-0.39 | −$0.27 | $229.7M | 6 |
| Current fiscal year (ends Dec 2026) | $-4.08 | $-4.19 | +$0.11 | $760.2M | 6 |
| Next fiscal year (ends Dec 2027) | $0.23 | $1.55 | -85.4% | $997.0M | 6 |
RARE options: expected move
Options price a move of about ±11.1% (±$1.93) by Nov 6, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±6.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 1 | 119.1% | ±3.9% |
| Nov 6, 2026 | 8 | 91.8% | ±11.1% |
| Nov 13, 2026 | 15 | 58.7% | ±9.7% |
| Nov 20, 2026 | 22 | 61.6% | ±12.3% |
| Nov 27, 2026 | 29 | 45.5% | ±10.4% |
| Dec 4, 2026 | 36 | 58.3% | ±14.7% |
| Dec 11, 2026 | 43 | 77.9% | ±21.4% |
| Dec 18, 2026 | 50 | 71.8% | ±21.2% |
30-day implied volatility 66.9% vs 49.1% realized over the last 30 trading days. Put/call ratio (volume) 0.05. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 20:55 UTC)
| Price | USD 16.78 |
|---|---|
| Change | ▼ 2.44% (down) |
| Previous Close | USD 17.2 |
| Open | USD 17.26 |
| Day Range | USD 16.71 – 17.63 |
| 52-Week Range | USD 12.73 – 39.89 |
| Volume | 2,801,674 shares |
| Market Cap | $1.65B |
| Exchange | NMS |
Technical Analysis (RARE)
Nexqual's technical model rates RARE "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 20:55 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 63.94 (neutral) |
| vs SMA50 | Below (USD 17.2) |
| MACD | -0.01 (negative) |
Analyst Ratings (RARE)
Wall Street analysts rate RARE "Buy" based on 21 analysts, with a mean price target of USD 26.25 (range USD 16–39), per Nexqual as of October 29, 2026 at 20:55 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 26.25 |
| High Target | USD 39 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 10 / 11 / 0 |
Earnings (RARE)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.75 |
| Revenue Estimate | $183.71M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.9 vs est -1 ▲ beat |
| 2026-03-31 | USD -1.54 vs est -1.46 ▼ miss |
| 2025-12-31 | USD -1.29 vs est -1.17 ▼ miss |
| 2025-09-30 | USD -1.81 vs est -1.21 ▼ miss |
Source: Nexqual, October 29, 2026 at 20:55 UTC.
Financials & Fundamentals (RARE)
| Total Revenue | $717.00M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +28.10% |
| Gross Margin | -20.78% |
| Operating Margin | -35.05% |
| Profit Margin | -81.73% |
| Current Ratio | 1.73 |
| Total Cash | $292.00M |
| Total Debt | $1.20B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$489.00M (-68.2% of revenue) |
Source: Nexqual, October 29, 2026 at 20:55 UTC.
Financial Health Score (RARE)
Nexqual rates Ultragenyx Pharmaceutical Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 20:55 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Critical — Gross margin -21%, operating -74% (last 12 months) |
| Balance Sheet | Mixed — $292M cash vs $1.20B debt |
| Cash Flow | Weak — FCF negative: -$489M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE not meaningful (negative equity); ROA -46.4% (last 4 quarters, SEC) |
Ownership (RARE)
| Insider Ownership | +3.43% |
|---|---|
| Institutional Ownership | +119.06% |
| Shares Outstanding | 98.59M |
| Float | 74.10M |
| Short % of Float | +21.13% |
Source: Nexqual, October 29, 2026 at 20:55 UTC.
Leadership (RARE)
Ultragenyx Pharmaceutical Inc. is led by Emil D. Kakkis, Founder, President, CEO & Director, per Nexqual as of October 29, 2026 at 20:55 UTC.
| Founder, President, CEO & Director | Emil D. Kakkis |
|---|---|
| Executive VP of Corporate Strategy & CFO | Howard Horn |
| Senior Vice President of Business Development & Alliance Management | Vimal Srivastava |
Major Backers & Investors (RARE)
Notable institutional backers of Ultragenyx Pharmaceutical Inc. include RTW Investments LP, AQR Capital Management, LLC, Two Sigma Investments, LP, according to Nexqual as of October 29, 2026 at 20:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 7.91% |
| AQR Capital Management, LLC | 6.65% |
| Two Sigma Investments, LP | 3.67% |
| Sands Capital Management, LLC | 3.2% |
| Jacobs Levy Equity Management, Inc. | 2.98% |
| Frontier Capital Management Company LLC | 2.89% |
| Fidelity | 1.07% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.25% |
| BlackRock | 10.81% |
| State Street | 6.25% |
Source: Nexqual, October 29, 2026 at 20:55 UTC.
From Ultragenyx Pharmaceutical Inc.'s Latest SEC 10-K Filing (filed 2026-02-18)
Key Strengths & Strategy (as disclosed to the SEC)
- We have an exclusive license from TAMU to a patent family filed in the U.S. and several foreign jurisdictions relating to UBE3A antisense oligonucleotides including GTX-102 and their use for the treatment of Angelman syndrome.
- Our success depends in part on our ability to protect our products, product candidates, processes, and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietary rights.
- Our intention is to expand our product portfolio and its geographic accessibility through the continued development of our proprietary pipeline or through strategic partnerships.
- We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Partnerships
- The program was acquired through an exclusive license agreement with Abeona Therapeutics, or Abeona, that was announced in May 2022.
- In November 2010, we entered into a license agreement with Saint Louis University, or SLU, wherein SLU granted us certain exclusive rights to intellectual property related to Mepsevii.
Legal & Regulatory Risks (Item 1A, quoted)
- Product liability lawsuits against us could cause us to incur substantial liabilities.
- Claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
- We may become involved in lawsuits to protect or enforce our patents or the patents of our licensors.
- Changes to patent laws in the U.S. and other jurisdictions could diminish the value of patents in general.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:55 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt